aif
patient
transfer
icu
hospit
sever
day
treatment
address
nosocomi
aspect
infect
follow
import
fact
mortal
rate
among
patient
patient
repres
hospit
deathssuccess
treatment
depend
upon
underli
diseas
specif
caus
organ
time
institut
therapi
bpredispos
factorsintubationicu
especi
patient
receiv
sedationantibiot
broadspectrum
agent
rapidli
chang
normal
flora
mouth
gastrointestin
gi
tractsurgeri
especi
thorac
abdomin
neurosurgeri
increas
risk
aspirationchron
lung
diseaseadvanc
ageimmunosuppress
cetiolog
bacteria
klebsiella
sp
escherichia
coli
pseudomona
aeruginosa
enterobact
sp
acinetobact
posit
bacteria
staphylococcu
aureu
less
commonanaerob
mouth
flora
ie
streptococci
gramneg
bacilli
ie
serratia
sp
xanthomona
sp
haemophilu
influenza
legionella
sp
candida
sp
aspergillu
spinfluenza
viru
streptococcu
pneumonia
miscellan
accord
preval
organ
hospit
tuberculosi
tb
typic
atyp
anoth
help
approach
consid
like
pathogen
accord
time
hospit
pneumonia
develop
lateonset
pneumonia
day
hospit
usual
character
resist
organ
dclinic
manifest
patient
icu
especi
intub
sedat
manifest
usual
symptom
pneumonia
cough
chest
pain
dyspnea
patient
neutropen
mount
inflammatori
respons
therefor
sputum
show
purul
materi
subtl
chang
oxygen
fever
clinic
deterior
clue
diagnosi
pneumonia
intub
patient
leukocytosi
leukopenia
first
manifest
occult
pneumonia
instanc
ie
pneumocysti
pneumonia
presenc
spontan
pneumothorax
first
indic
pulmonari
involv
thick
foulsmel
sputum
characterist
anaerob
aspir
pneumoniaediagnosison
chest
xray
look
new
chang
infiltratesobtain
sputum
gram
stain
immedi
everi
patientrememb
concept
colon
versu
true
infect
distinct
sometim
difficultb
aggress
tri
obtain
diagnosi
ie
bronchoalveolar
lavag
bal
transtrach
aspir
commonli
employedobtain
stain
ie
acidfast
bacilli
stain
afb
giemsa
wet
prep
order
serolog
appropri
ie
legionella
fungal
serolog
cryptococc
antigen
cie
rememb
microbiolog
pattern
hospit
ftreatment
optionsempir
option
commonli
util
icubetalactam
plu
aminoglycosid
ie
piperacillin
tobramycin
cephalosporin
plu
aminoglycosid
ie
ceftazidim
gentamicin
clindamycin
plu
gentamicinclindamycin
plu
quinolon
ie
ciprofloxacin
imipenemcilastatin
plu
aminoglycosidecephalosporin
plu
fluoroquinoloneadd
trimethoprimsulfamethoxazol
tmpsmx
pneumocysti
carinii
pneumonia
suspectedadd
erythromycin
azithromycin
mg
iv
qd
erythromycin
g
iv
h
legionella
suspect
tmpsmx
mgkgd
tmp
doxycyclin
mg
iv
hrifampin
mg
iv
hamphotericin
b
mgkgddurat
therapi
well
defin
author
agre
treat
gramneg
anaerob
pneumonia
day
gramposit
process
usual
treat
day
atyp
pneumonia
receiv
week
antimicrobi
therapi
candida
pneumonia
requir
prolong
treatment
g
amphotericin
b
total
dose
gpreventionpreop
postop
measur
prevent
pneumoniaidentif
highrisk
patientstreat
respiratori
infect
remov
respiratori
secretionsinstruct
therapi
expand
patient
lung
ie
chest
physiotherapi
incent
spirometri
proper
hand
washingappropri
mainten
inus
respiratori
therapi
equipmentus
steril
fluid
nebulizersprop
use
singledos
multidos
medic
respiratori
therapi
proper
steril
disinfect
reusabl
respiratori
equipmentprop
suction
respiratori
tractprotect
patient
infect
patient
staff
acommon
organ
streptococcu
pneumonia
mycoplasma
pneumonia
haemophilu
influenza
klebsiella
sprespiratori
virus
influenza
b
adenoviru
respiratori
syncyti
viru
parainfluenza
legionella
sp
bother
less
common
organ
pneumocysti
carinii
mycobacterium
tuberculosi
cryptococcu
sp
chlamydia
psittaci
histoplasma
sp
nocardia
sp
ccommon
manifestationsfev
cough
dyspnea
sputum
product
usual
purul
caseshypoxemia
commonanxietyleukocytosi
also
leukopenia
sever
infect
duncommon
present
patient
especi
neutropen
posttransplant
eclin
clue
diagnosisacut
onset
bacteri
viral
aspir
tularemia
pneumocysti
subacut
onset
viral
legionella
haemophilu
sp
mycoplasma
q
fever
psittacosi
chlamydia
pneumocysti
aerogen
rout
segmenthematogen
commonli
base
blood
flow
preferenti
area
fassociationsbird
psittacosisturtl
typhoiddog
pasteurella
multocida
cattl
q
feverrabbit
tularemiaair
condition
legionella
copd
smoke
h
influenza
pseudomona
aeruginosa
hide
anthraxforeign
travel
echinococcu
paragonimiasisbarrack
neisseria
meningitidi
group
streptococcu
gtreatment
empir
treatment
usual
dictat
geograph
background
clinic
present
host
statuslevofloxacin
mgorceftriaxon
g
iv
plu
azithromycin
mg
iv
streptococcu
pneumonia
haemophilu
influenza
quinolon
moxifloxacin
levofloxacin
ertapenem
g
h
ceftriaxon
g
h
legionella
sp
mycoplasma
pneumonia
chlamydia
pneumonia
moxifloxacin
mg
iv
qd
levofloxacin
mg
iv
qd
doxycyclin
mg
iv
qd
pseudomona
aeruginosa
meropenem
g
iv
h
cefepim
g
iv
h
amikacin
g
iv
h
multidrug
resist
p
aeruginosa
colistin
mg
iv
h
influenza
ab
avian
influenzaa
oseltamivir
tamiflu
mg
po
h
plu
rimantadin
mg
poavian
influenza
influenza
viru
type
follow
close
contact
infect
poultri
sever
outbreak
human
identifi
asia
flulik
symptom
vagu
gastrointestin
complaint
rapidli
progress
acut
respiratori
failur
diagnosi
hemagglutininspecif
rtpcr
avian
influenza
treatment
antivir
given
earli
includ
oseltamivir
mg
amantadin
rimantadin
hcomplic
hpersist
feverempyemaobstructionlung
abscessresist
organismfocu
infect
term
given
world
health
organ
describ
rapidli
progress
respiratori
ill
document
outbreak
china
hong
kong
vietnam
singapor
canada
presum
pathogen
coronaviru
spread
person
person
via
droplet
sewag
water
potenti
human
fece
hypothes
bat
primari
reservoir
diseas
mortal
rate
sar
high
twostag
ill
prodrom
includ
fever
malais
headach
myalgia
diarrhea
may
occurrespiratori
phase
nonproduct
cough
dyspnea
rapidli
progress
respiratori
failur
current
treatment
avail
ill
except
support
care
intens
care
unit
prevent
measur
sar
mainli
focus
travel
advisori
countri
citi
activ
outbreak
effort
underway
prepar
vaccin
prevent
sar
amor
case
sepsi
associ
mortal
estim
occur
annual
despit
improv
antimicrobi
therapi
support
care
incid
mortal
associ
sepsi
declin
part
consequ
array
medic
advanc
place
patient
increas
risk
develop
infect
potenti
sepsisbsepsi
relat
disordersdefinitionsbacteremia
posit
blood
cultur
may
transient
sepsi
clinic
evid
suggest
infect
plu
sign
system
respons
infect
follow
tachypnea
respir
breath
per
minut
patient
mechan
ventil
minut
volum
lmin
tachycardia
heart
rate
beat
per
minut
hyperthermia
hypothermia
core
rectal
temperatur
sepsi
syndrom
may
also
consid
incipi
septic
shock
patient
later
becom
hypotens
clinic
diagnosi
sepsi
outlin
plu
evid
alter
organ
perfus
one
follow
higher
absenc
pulmonari
cardiovascular
diseas
lactat
level
upper
limit
normaloliguria
document
urin
output
mlkg
bodi
weight
least
h
patient
urinari
cathet
place
acut
alter
mental
statusposit
blood
cultur
requir
earli
septic
shock
clinic
diagnosi
sepsi
syndrom
outlin
plu
hypotens
systol
blood
pressur
mmhg
decreas
baselin
systol
blood
pressur
last
h
respons
convent
therapi
intraven
fluid
administr
pharmacolog
intervent
refractori
septic
shock
clinic
diagnosi
sepsi
syndrom
outlin
plu
hypotens
systol
blood
pressur
mmhg
decreas
baselin
systol
blood
pressur
last
h
despit
adequ
volum
resuscit
requir
vasopressor
cpathophysiolog
cell
wall
gramneg
bacteria
contain
protein
lipid
lipopolysaccharid
endotoxin
lipopolysaccharid
three
compon
ospecif
polysaccharid
rcore
lipid
lipid
may
major
culprit
initi
endotox
symptom
compon
endotoxin
stimul
releas
tissu
necrosi
factor
tnf
also
activ
complement
pathway
sepsi
syndrom
caus
endotheli
damag
follow
endotoxinstimul
activ
neutrophil
coagul
complement
macrophag
macrophag
stimul
releas
tnf
interleukin
leukotrien
thromboxan
cardioact
substanc
endotoxemia
markedli
increas
risk
myocardi
depress
multipl
organ
failur
patient
posit
blood
cultur
sever
endotoxemia
time
mortal
endotoxemiadprior
treatment
sepsisearli
recognitioncardiovascularpulmonari
supportfluid
resuscitationpressor
agentsempir
antibiot
therapyoth
immunotherapeut
agent
investig
corticosteroid
effect
drainag
foci
infect
eprognosi
mortal
sepsi
function
sever
physiolog
derang
durat
ill
number
organ
system
failur
organ
system
includ
limit
lung
kidney
liver
pulmonari
system
becom
dysfunct
result
clinic
entiti
known
adult
respiratori
distress
syndrom
ard
sequenc
term
multipleorgan
dysfunct
syndrom
mod
mod
common
caus
demis
patient
experi
uncontrol
inflamm
infectionf
activ
protein
c
presenc
coagul
abnorm
major
problem
patient
sever
sepsi
septic
shock
report
suggest
supplement
activ
protein
c
may
produc
clinic
benefit
decreas
mortal
rate
greater
benefit
activ
protein
c
observ
acut
ill
patient
apach
ii
score
evid
show
patient
receiv
activ
protein
c
lower
incid
multiorgan
system
failur
greater
risk
seriou
bleed
includ
fatal
intracrani
hemorrhag
care
select
patient
done
order
identifi
benefit
therapi
aclin
case
definit
see
tabl
sever
febril
ill
rash
erythroderma
follow
desquam
hypotens
syncop
multipl
organ
system
involv
least
four
follow
mucou
membran
gi
muscular
central
nervou
system
cn
renal
hepat
hematolog
cardiopulmonari
metabol
hypotens
probabl
due
smallvessel
capillari
leakag
extravascular
accumul
fluid
edema
blood
cultur
usual
negativeacut
episod
follow
desquamationno
evid
caus
scarlet
fever
kawasaki
diseas
rocki
mountain
spot
fever
etc
bepidemiolog
clinic
featuresaffect
mostli
young
menstruat
women
tampon
use
especi
continu
use
reli
brand
studi
aureu
colon
vagina
recurr
rate
decreas
number
report
casesalso
occur
nonmenstru
women
men
children
colon
focal
infect
aureu
includ
postop
infect
common
occurr
surgeri
fatal
rate
cetiolog
exotoxin
aureu
appear
caus
diseas
recent
streptococci
shown
caus
syndromeddifferenti
diagnosi
kawasaki
diseas
scarlet
fever
leptospirosi
rocki
mountain
spot
fever
measlesetreat
import
treatment
volum
expans
correct
hypotens
remov
tampon
present
menstruat
women
debrid
wound
etc
administr
antistaphylococc
antibiot
cultur
obtain
steroid
proven
effect
alter
outcom
aacut
mening
medic
emerg
requir
earli
recognit
rapid
diagnosi
precis
antimicrobi
therapi
aggress
icu
supportetiolog
agent
streptococcu
pneumonia
common
caus
adult
neisseria
mening
common
among
group
young
individu
children
haemophilu
influenza
common
children
year
age
staphylococcu
aureu
epidermidi
seen
elderli
postop
cn
shunt
listeria
monocytogen
usual
mistaken
diphtheroid
contaminantsstreptococci
pneumonia
especi
group
b
neonat
diseasegramneg
bacilli
surgeri
trauma
mycobacterium
tuberculosi
increas
frequenc
cryptococcu
usual
immunosuppress
patient
ie
acquir
immun
defici
syndrom
aid
impair
cellmedi
immun
syphili
present
variabl
herp
simplex
toxoplasma
present
meningoenceph
brain
abscessnaegleria
epidemiolog
histori
paramountoth
virus
ie
echoviru
st
loui
equin
western
enceph
associ
epidemiolog
organismssumm
fall
coxsacki
echoviru
leptospiraprevi
mening
pneumonia
alcohol
pneumonia
young
adult
n
mening
elderli
pneumonia
listeria
gramneg
bacillilymphoma
cryptococcu
sppetechia
n
meningitidi
echovirussinus
h
influenza
pneumonia
anaerob
bacteria
cellul
aerob
gramposit
cocci
brain
abscess
mix
floraswim
fresh
water
amoebasoth
famili
member
mening
n
meningitidi
water
contact
leptospirahospit
acquir
gramneg
bacilli
staphylococcu
candidahead
trauma
close
fractur
pneumonia
gramneg
bacillicraniotomi
gramneg
bacilli
staphylococcicerebrospin
fluid
rhinorrhea
pneumonia
cerebrospin
fluid
csf
find
see
tabl
diagnost
approachord
antigen
detect
h
influenza
pneumonia
n
meningitidi
obtain
highvolum
csf
afb
concentr
fungal
cultur
ml
csf
normal
virus
suspect
repeat
lumbar
punctur
lp
hupon
admiss
obtain
serolog
viral
infect
ie
st
loui
enceph
california
enceph
obtain
serolog
serum
csf
fungal
infectionspolymeras
chain
reaction
pcr
may
help
especi
tb
cytomegaloviru
cmv
infect
treatmentin
acut
ill
patient
goal
therapi
institut
treatment
patholog
process
inflamm
produc
irrevers
progress
andor
death
time
essenti
situat
empir
therapi
institut
immedi
diagnosi
made
base
recognit
commun
versu
hospit
andor
postop
process
communityacquir
mening
usual
treatment
includ
thirdgener
cephalosporin
ie
cefotaxim
g
iv
h
ceftriaxon
g
h
vancomycin
ad
regimen
cultur
suscept
result
avail
bpneumococc
meningitispneumococc
mening
still
common
caus
bacteri
mening
adult
underli
diseas
sickl
cell
diseas
splenectomi
splenic
dysfunct
hypogammaglobulinemia
alcohol
head
trauma
csf
fistula
chronic
pulmonari
hepat
renal
diseaseassoci
infect
pneumonia
otiti
bacteremia
endocard
mastoiditistherapi
ceftriaxon
gd
vancomycin
gd
given
betalactam
resist
note
local
chaemophilu
meningitisunderli
diseas
adult
alcohol
compromis
host
defens
head
traumaassoci
infect
pneumonia
sinus
otiti
secondari
case
occur
close
contactstherapi
cefotaxim
g
iv
h
ceftriaxon
g
iv
h
chloramphenicol
mg
po
h
week
iv
po
switch
dmeningococc
meningitismeningococc
mening
seen
primarili
children
adolesc
young
adult
secondari
infect
close
contact
occur
predispos
factor
includ
complement
defectsdissemin
neisseri
infect
often
recurr
person
defici
waterhousefrederickson
syndrom
acut
often
fatal
syndrom
septic
shock
associ
massiv
adren
necrosi
associ
bacteremia
due
organ
requir
earli
recognit
antibiot
therapi
especi
aggress
icuhemodynam
supportearli
antimicrobi
therapi
need
ceftriaxon
g
iv
h
prefer
iv
therapi
altern
meropenem
g
h
administ
elisteria
mening
listeria
import
caus
bacteremia
mening
particularli
elderli
epidemiolog
histori
import
therapi
ampicillin
g
h
meropenem
excel
vitro
activ
listeria
f
staphylococcu
aureu
staphylococcu
epidermidi
infect
organ
common
neurosurgeri
andor
ventricular
periton
shunt
placementtherapymethicillin
sensit
cefotaxim
g
iv
h
cefepim
g
iv
h
methicillin
resist
linezolid
mg
iv
h
vancomycin
g
iv
h
infect
shunt
may
need
remov
earli
cours
therapi
patient
respond
repeat
lp
day
need
order
reach
decis
persist
growth
organ
despit
adequ
therapi
ggramneg
bacilliinfect
gramneg
bacilli
challeng
treat
due
high
morbid
mortal
develop
resist
occur
therapi
especi
enterobact
sp
organ
respond
ceftriaxon
cefotaxim
ceftazidim
pseudomona
aeruginosa
ceftazidim
g
iv
h
drug
choic
given
gentamicin
h
hcomplic
bacteri
meningitisbrain
abscess
usual
follow
trauma
contigu
infect
hematogen
disseminationsubdur
empyema
primarili
diseas
young
elderli
may
complic
neurosurgeri
subdur
hematomaepidur
abscess
usual
accompani
focal
osteomyel
subdur
empyemaal
caus
mix
bacteria
usual
requir
drainag
well
prolong
iv
antibiot
therapyiherp
meningitisenceph
herp
meningitisenceph
devast
necrot
type
enceph
tempor
spike
electroencephalogram
eeg
characterist
treatment
given
acyclovir
mgkg
h
high
dose
week
care
attent
hydrat
mandatori
avoid
renal
insuffici
aopportunist
infect
common
caus
morbid
mortal
patient
human
immunodefici
viru
hiv
patient
cell
risk
develop
sever
infecti
complic
approach
depict
tabl
current
therapeut
approachespulmonari
diseasediseas
due
pneumocysti
carinii
pneumocysti
jirovecii
pneumonia
pcp
tabl
diseas
due
tuberculosi
start
least
four
drug
prefer
five
inh
mgd
rifampin
mgd
pyrazinamid
ciprofloxacin
mg
po
bid
ethambutol
mgkgdif
tb
sensit
inh
andor
rifampin
continu
month
icu
tb
resist
either
drug
inh
rifampin
multipl
drug
resist
continu
drug
adjust
accord
sensit
prognosi
poorfollow
liver
function
test
initi
weekli
later
monthlyif
patient
use
po
drug
give
iv
inh
rifampin
dose
im
streptomycin
gd
pulmonari
diseas
due
histoplasma
capsulatum
initi
therapi
amphotericin
b
mgkgdsearch
site
involv
ie
bone
marrow
biopsi
lumbar
punctur
chest
xray
barium
enema
small
bowel
seri
patient
stabl
switch
fluconazol
mg
po
bid
pulmonari
diseas
due
legionella
spiniti
therapi
erythromycin
g
ivdif
patient
respond
add
rifampin
mgd
andor
ciprofloxacin
mg
iv
h
pulmonari
diseas
due
bacteria
common
organ
streptococcu
pneumonia
haemophilu
influenza
pseudomona
especi
sinus
present
add
antibacteri
therapi
empir
admissionticarcillinclavulan
acid
g
iv
h
also
cover
anaerob
sinus
piperacillintazobactam
g
iv
hcefuroxim
g
iv
hadjust
cultur
sensit
becom
avail
pulmonari
diseas
due
aviumintracellular
ethambutol
mgkgd
po
plu
clarithromycin
mg
po
h
azithromycin
mg
po
h
plu
rifampintreat
given
least
month
neg
sputum
mai
enter
pathogen
patient
aid
see
tabl
cn
infect
aidscryptococc
meningitisacut
amphotericin
b
mgkgd
plu
mgkgd
patient
stabl
improv
switch
fluconazol
mgd
po
monthsmainten
fluconazol
mgd
po
toxoplasmosispyrimethamin
mg
po
load
dose
follow
mg
po
daili
folin
acid
mg
po
daili
iv
present
avail
sulfadiazin
g
po
h
plu
leucovorin
mg
po
h
cmv
includ
retin
ganciclovir
mgkg
iv
h
day
initi
therapi
foscarnet
mgkg
iv
h
day
initi
therapi
lifelong
suppress
therapi
valganciclovir
mg
po
h
herp
simplexacyclovir
mgkg
iv
h
syphiliscrystallin
penicillin
million
ud
daysceftriaxon
gd
iv
day
cimport
fact
rememb
treat
hivinfect
patient
icupati
may
one
infect
timeblood
precaut
institut
immedi
avoid
unnecessari
exposurenoninfecti
process
ie
tumor
mimic
infectionspati
requir
full
physic
examin
daili
includ
mouth
perirect
area
eyessuperinfect
common
ie
fungal
resist
bacteria
fever
persist
consid
lumbar
punctur
liver
bone
marrow
biopsyobtain
count
recent
clonecod
statu
need
establish
earlyprivaci
respect
toward
patient
essenti
mandatori
ath
number
critic
ill
patient
impair
host
defens
mechan
admit
icu
dramat
increas
recent
year
knowledg
recognit
basic
defici
enabl
physician
predict
type
site
infect
allow
institut
earli
empir
therapi
see
tabl
bimmunocompromis
patient
admit
icu
categor
accord
time
acquisit
infect
hospitalacquir
infect
differ
etiolog
agent
compar
commun
despit
basic
immunolog
defect
ahand
wash
singl
import
procedur
prevent
infectionbimprov
nutrit
statu
great
import
outcom
infectionscremov
bladder
cathet
soon
possibledcomplet
daili
physic
examin
mandatoryegram
stain
singl
best
least
expens
test
earli
diagnosi
sever
infect
ie
pulmonari
soft
tissu
mening
fhypothermia
especi
elderli
patient
suggest
sepsisgcentr
cathet
chang
everi
dayshperipher
line
chang
everi
daysiif
prolong
icu
stay
expect
earli
placement
subcutan
cathet
recommendedjpati
high
fever
requir
special
attent
fluid
managementkantibiot
interact
mani
drug
see
previou
tabl
ldruginduc
fever
uncommon
common
agent
antibiot
phenytoin
mfever
may
last
sever
day
even
appropri
antimicrobi
therapi
institutednclos
follow
clinic
situat
import
laboratori
result
antibiot
kinet
pharmacokinet
antibiot
depend
sever
factorsth
volum
distribut
vd
antimicrobi
calcul
documentclass
minim
usepackag
amsmath
usepackag
wasysym
usepackag
amsfont
usepackag
amssymb
usepackag
amsbsi
usepackag
mathrsf
usepackag
upgreek
setlength
oddsidemargin
begin
document
rm
v
rm
frac
rm
rm
c
rm
p
end
document
total
amount
antibiot
bodi
cp
antibiot
plasma
concentrationrepetit
dose
antibiot
depend
principl
minim
plasma
concentr
cmin
documentclass
minim
usepackag
amsmath
usepackag
wasysym
usepackag
amsfont
usepackag
amssymb
usepackag
amsbsi
usepackag
mathrsf
usepackag
upgreek
setlength
oddsidemargin
begin
document
rm
c
rm
min
frac
rm
rm
v
rm
end
document
dose
n
dose
interv
express
halflivesth
plasma
concentr
steadi
state
css
antimicrobi
estim
util
follow
formula
documentclass
minim
usepackag
amsmath
usepackag
wasysym
usepackag
amsfont
usepackag
amssymb
usepackag
amsbsi
usepackag
mathrsf
usepackag
upgreek
setlength
oddsidemargin
begin
document
rm
c
rm
ss
frac
hbox
dose
per
half
life
rm
rm
v
rm
end
document
b
antibiot
adjust
renal
dysfunct
critic
ill
patient
common
patient
receiv
aminoglycosid
dosag
modif
requir
accord
aminoglycosid
clearanc
documentclass
minim
usepackag
amsmath
usepackag
wasysym
usepackag
amsfont
usepackag
amssymb
usepackag
amsbsi
usepackag
mathrsf
usepackag
upgreek
setlength
oddsidemargin
begin
document
hbox
aminoglycosid
clearanc
c
rm
cr
rm
rm
end
document
ccr
creatinin
clearanc
mlminto
estim
creatinin
clearanc
cockcroft
gault
formula
util
documentclass
minim
usepackag
amsmath
usepackag
wasysym
usepackag
amsfont
usepackag
amssymb
usepackag
amsbsi
usepackag
mathrsf
usepackag
upgreek
setlength
oddsidemargin
begin
document
rm
c
rm
cr
rm
mlmin
frac
rm
rm
age
time
rm
weight
rm
cr
time
rm
end
document
cr
serum
creatinin
mgdl
anoth
modif
formula
spyker
guerrant
method
documentclass
minim
usepackag
amsmath
usepackag
wasysym
usepackag
amsfont
usepackag
amssymb
usepackag
amsbsi
usepackag
mathrsf
usepackag
upgreek
setlength
oddsidemargin
begin
document
rm
c
rm
cr
rm
mlmin
frac
rm
rm
age
time
rm
rm
time
rm
cr
rm
cr
end
document
c
antibiot
level
clinic
employ
antibiot
level
depict
tabl
fact
atyp
mycobacteria
commonli
encount
critic
care
set
depict
tabl
